Pathware is producing point-of-care quality assessment tools for fine-needle aspirated biopsies. Bringing point of care evaluation to hospitals of any size delivering better patient outcomes and increased clinical revenues. Pathware’s hardware and software simplifies and accelerates digital pathology workflows while eliminating repeat procedures. Bioptic™, their cloud-based sample management platform, returns a biopsy quality determination in minutes while the patient is still present. Twenty percent of needle biopsies fail to collect a sufficient sample to make a diagnosis. Consequently, large medical facilities are forced to staff pathologists during routine biopsy procedures to perform Rapid Onsite Evaluation (“ROSE”), taking them away from vital lab-based diagnosis work. Pathologists are in increasingly short supply worldwide, with many small and rural facilities being unable to implement ROSE with the consequent impact upon workload, delay in diagnosis and sub-optimal patient outcome. Pathware is working to add full diagnostic capabilities to Bioptic. Level Eight co-led an oversubscribed $7m Series A round announced in April 2022.